Toward an Effective Ebola Virus Vaccine.
Long-term control of viral outbreaks requires the use of vaccines to impart acquired resistance and ensuing protection. In the wake of an epidemic, established immunity against a particular disease can limit spread and significantly decrease mortality. Creation of a safe and efficacious vaccine against Ebola virus (EBOV) has proven elusive so far, but various inventive strategies are now being employed to counteract the threat of outbreaks caused by EBOV and related filoviruses. Here, we present a current overview of progress in the field of Ebola virus vaccine development.
Department of Microbiology and Immunology, Sidney Kimmel Medical College,Thomas Jefferson University, Philadelphia, Pennsylvania 19107; email: Matthias.Schnell@jefferson.edu.
Rohan
R
Keshwara
Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Reed F
RF
Johnson
Department of Microbiology and Immunology, Sidney Kimmel Medical College,Thomas Jefferson University, Philadelphia, Pennsylvania 19107; email: Matthias.Schnell@jefferson.edu.
Matthias J
MJ
Schnell
D000256:Adenoviridae; D000818:Animals; D035843:Biomedical Research; D055808:Drug Discovery; D046129:Ebola Vaccines; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control*; D006801:Humans; D007116:Immunization, Passive; D053758:Nanoparticles; D011820:Rabies virus; D014611:Vaccination; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D058425:Vaccines, Virus-Like Particle; D018116:Vesiculovirus
D046129:Ebola Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D058425:Vaccines, Virus-Like Particle
EBOV vaccine; immunization; vector